In this webinar, the panel reviewed and discussed incorporation of immune checkpoint inhibitors in both first-line treatment for advanced disease and in the adjuvant setting, their impact on subsequent treatment, the current status of targeted therapy and the testing of biomarkers and upcoming combination treatment strategies in patients with gastric/GEJ cancer.
- To understand the current paradigm of incorporating checkpoint inhibitors both in the first line advanced disease and post-operative adjuvant settings and its impact on subsequent treatment in gastric/GEJ adenocarcinoma
- To review the current status of HER2 and other targeted therapy and understand when and how to test for these biomarkers in the patient’s treatment pathway
- To appreciate the upcoming strategies of improving on immunotherapy in gastric cancer
- To review the above objectives via a short clinical cased discussion as well as audience Q&A session